LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and biomarkers measuring serum and cardiac structure and function, expected in the first half of 2024 NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), […]